Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Role of DHA Monoglyceride (MAG-DHA) in the Resolution of Pulmonary Inflammation of Patients With Cystic Fibrosis.

NCT02518672 is registered in ClinicalTrials.gov with SCF Pharma as lead sponsor.

NCT NCT02518672
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02518672 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Role of DHA Monoglyceride (MAG-DHA) in the Resolution of Pulmonary Inflammation of Patients With Cystic Fibrosis.
Lead sponsor
SCF Pharma
Phase
Phase 2
Overall status
Terminated
Start date
October 31, 2015
Completion date
November 30, 2016
Enrollment
11 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

cystic fibrosis